Trial Profile

A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omaveloxolone (Primary)
Indications Mitochondrial myopathies
Focus Therapeutic Use
Acronyms MOTOR
Sponsors Reata Pharmaceuticals

Most Recent Events

02 Jan 2020 Primary endpoint has not been met. (Measure the change of peak workload (in watts/kg) during exercise testing), according to results published in the Neurology.
02 Jan 2020 Results published in the Neurology
02 Apr 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com